Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
27 studies found for:    Open Studies | "Gout"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting Gout: Allopurinol vs. Febuxostat
Conditions: Gout;   Chronic Kidney Diseases
Interventions: Drug: Allopurinol;   Drug: Febuxostat;   Drug: Placebo, vehicle control (Febuxostat-shaped);   Drug: Placebo, vehicle control (Allopurinol-shaped)
2 Unknown  Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout
Conditions: Hyperuricemia;   Gout
Intervention: Drug: levotofisopam
3 Recruiting Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study
Conditions: Gout;   Chronic Kidney Diseases
Interventions: Drug: Anakinra 100mg and Placebo Depo-Medrone;   Drug: Depo-Medrone 120mg and Placebo (Anakinra)
4 Not yet recruiting Novel Methods for Ascertainment of Gout Flares -A Pilot Study
Condition: Gout
Interventions: Device: IVR (Phone call);   Device: RheumPro (Smartphone application)
5 Not yet recruiting SToRytelling to Improve DiseasE Outcomes in GOut: The STRIDE-GO 2 Study
Conditions: Gout;   Low Medication Adherence;   Health Related Quality of Life
Intervention: Behavioral: Improvement of Medication Adherence
6 Recruiting Colchicine Or Naproxen Treatment for ACute gouT
Condition: Gout
Interventions: Drug: Low-dose colchicine;   Drug: Naproxen
7 Not yet recruiting Study of URC102 to Assess the Safety and Efficacy in Gout Patients
Conditions: Gout;   Hyperuricemia
Interventions: Drug: URC102;   Drug: Placebo
8 Recruiting Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients
Conditions: Gout;   Hyperuricemia
Interventions: Drug: URC102 0.25mg;   Drug: URC102 0.5mg;   Drug: URC102 1.0mg;   Drug: URC102 2.0mg;   Drug: placebo
9 Unknown  The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome
Conditions: Antiphospholipid Syndrome;   Endothelial Dysfunction;   Hyperuricemia;   Gout;   Metabolic Syndrome
Intervention:
10 Recruiting Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
Condition: Gout
Interventions: Drug: Bucillamine;   Drug: Colchicine
11 Recruiting Observational Study of the Use of KRYSTEXXA® in Refractory Chronic Gout
Condition: Chronic Gout
Intervention: Biological: pegloticase
12 Recruiting A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
Condition: Gout
Interventions: Drug: Placebo;   Drug: AC-201;   Drug: Febuxostat
13 Not yet recruiting Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Condition: Gout
Intervention: Drug: Denosumab
14 Recruiting Elastography as Gouty Arthropathy Outcome (EGO)
Condition: Gout
Intervention:
15 Recruiting Genetics of Hyperuricemia Therapy in Hmong
Condition: Hyperuricemia, Gout
Intervention: Drug: Allopurinol
16 Recruiting Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
Condition: Gout
Intervention: Biological: Pegloticase
17 Unknown  Rheumatology Informatics System for Effectiveness
Conditions: Rheumatoid Arthritis;   Osteoarthritis;   Gout
Intervention:
18 Unknown  Impact of Unapproved Drug Initiative on Colchicine Use
Condition: Gout
Intervention:
19 Recruiting Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
Condition: Gout
Interventions: Drug: SEL-110;   Biological: SEL-212;   Biological: SEL-037
20 Recruiting Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
Condition: Gout
Intervention: Drug: Febuxostat

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Indicates status has not been verified in more than two years